SynthesisFrontiers in immunology2026
Anti-phospholipid antibodies as a risk factor for renal injury in patients with systemic lupus erythematosus: a comprehensive analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although the existence of antiphospholipid antibodies (aPL) has been extensively documented as a risk factor for thrombocytopenia, hemolytic anemia, and recurrent miscarriage, their contribution to renal damage in the context of the systemic lupus erythematosus (SLE) is yet to be defined. This meta-analysis investigated the association between aPL and renal injury among patients with SLE. Methods: A systematic literature search was conducted to determine publications that examined the relationship between the level of aPL and renal functioning in SLE patients in four electronic databases (PubMed, Cochrane Library, Embase, and Web of Science). Funnel plots and Egger's test were utilized to assess the presence of publication bias. Sensitivity analysis and the trim-and-fill method were used in the evaluation of the stability of the results. Subgroup analyses were performed according to study design, geographic region, aPL subtype, publication date, and pathological type of lupus nephritis. Also, the cumulative meta-analyses were conducted by ranking the studies based on the year of publication, sample size, and the Newcastle-Ottawa Scale score. Results: A total of 34,353 publications were retrieved up to September 12, 2025. After screening, a total of 70 studies (18 case-control, 23 cohort, and 29 cross-sectional) involving 12,456 SLE patients were included. The pooled OR for renal injury in aPL-positive versus aPL-negative patients was 2.09 (1.70-2.58). Subgroup analysis revealed anti-cardiolipin (aCL), lupus anticoagulant (LA), and antiphospholipid syndrome significantly increased the risk of renal injury compared with control groups, 108with OR of 1.71 (1.34-2.18), 2.43 (1.64-3.61), 2.07 (1.48-2.89), respectively. In contrast, no statistically significant increase in renal injury risk was observed in groups positive for anti-β2-glycoprotein I and aPS/PT. Cumulative meta-analyses consistently demonstrated an increased risk of renal injury in aPL-positive patients, and this association remained stable across different publication years, sample sizes, and study quality. Conclusions: Seropositivity for aPL was significantly associated with an increased risk of renal injury in SLE patients, primarily driven by LA and aCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.